Adagene Gains NMPA Clearance for ADG138 IND
SAN DIEGO and SUZHOU, China — September 22, 2026 Adagene announced that China’s National Medical Products Administration (NMPA) has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN DIEGO and SUZHOU, China — September 22, 2026 Adagene announced that China’s National Medical Products Administration (NMPA) has...
